In a poignant tribute to the late Sarah Harding, a beloved member of the iconic girl group Girls Aloud, a pioneering breast cancer study has been launched in her honour. The Sarah Harding Breast Cancer Appeal, founded after Harding’s passing in 2021 at the age of 39, has funded vital research at the Christie Hospital in Manchester, where she was treated.
Dr. Hannah Harrison has been appointed as the Sarah Harding Young Women’s Breast Cancer Fellow, and will be spearheading a new study that aims to better understand the risk factors and potential preventative measures for breast cancer in women in their 30s. Harding’s own battle with the disease, which had spread to other parts of her body, inspired her last wish to help others facing similar challenges.
“Breast cancer is the leading cause of death for young women, and prevention is the best way to change this,” Dr. Harrison told BBC Radio Manchester. “We couldn’t do this without Sarah.”
The study, known as the Breast Cancer Risk Assessment in Young Women (BCAN-RAY) study, is organised by the Christie and funded by the Sarah Harding Breast Cancer Appeal. Researchers hope that their findings will result in all women receiving a risk assessment for breast cancer when they reach the age of 30, allowing for early identification of those most at risk.
In addition to the BCAN-RAY study, the appeal has also provided a grant for Dr. Harrison to establish her own laboratory, focused on exploring alternative treatments for young women with breast cancer. “The goal of the work is that we’ll find a way to reduce the number of breast cancer cases and the number of lives lost – especially within this young population of women,” she explained.
The Girls Aloud bandmates, who were devastated by Harding’s passing, have expressed their support for the initiative. In a statement, they said they were “thrilled” with the progress being made in Sarah’s name, noting that “Sarah believed in the power of progress, and so to have a dedicated researcher focusing on this important work is hugely significant.”
Rachel Kendall, the deputy chief executive of The Christie Charity, praised the role of Harding’s family, friends, and bandmates in rallying behind the fundraising efforts. “I think Sarah’s story really resonates with younger women and people who grew up, listening to Girls Aloud and knew who Sarah was and who the band are,” she said. “That’s really important – reaching those women that might be at increased risk and then making sure that we can help them.”
As the research progresses, the legacy of Sarah Harding’s bravery and determination to help others will continue to inspire and drive the medical community in their quest to better understand and combat breast cancer in young women.